Perazine vs placebo
Quality of life ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
14 questions · 14 findings · 7 reviews · Schizophrenia
No studies found 13 · 92.9%GRADE not reported 1 · 7.1%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs placebo
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
- Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Sildenafil vs placebo
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
- Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Benzodiazepines vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
CHOLINERGIC DRUGS vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- Cholinergic medication for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Levetiracetam vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Buspirone vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
FATTY ACID ‐ ETHYL‐EPA vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Ginkgo biloba vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Melatonin vs placebo or no treatment
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
POLYPEPTIDE ‐ CERULETIDE vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
DOPAMINERGIC DRUGS vs placebo
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
- Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
PIMOZIDE vs placebo
Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found